Search Abstracts

Background People with HIV (PWH) have an increased risk of cardiovascular disease (CVD), driven by persistent immune activation and metabolic disturbances, despite successful antiretroviral therapy (ART). Alterations in some immune parameters and metabolites have been associated with the CVD onset. However, specific lipidomic, metabolomic, and immunological biomarkers preceding CVD in PWH are still unknown. Methods…

Background Statin use will likely increase in persons with HIV (PWH) at low-to-moderate CVD risk given the cardiovascular disease (CVD) prevention benefit demonstrated by the REPRIEVE trial. However, real-world benefit of statins may be lower than expected with insufficient low-density lipoprotein (LDL) reductions. Older studies reported that few PWH on statins experienced timely LDL reductions,…

Background People with HIV (PWH) have a higher incidence of cardiovascular disease, including heart failure (HF) and acute myocardial infarction (AMI) than people without HIV (PWoH). In the general population, 30-day readmissions following hospitalizations for HF and AMI are common, and reducing these readmissions is a national quality of care priority. This study compares the 30-day…

Background Integrase strand transfer inhibitors (INSTIs) have good lipid profiles but some studies have reported increased risk of dyslipidaemia and hypertension, particularly when combined with tenofovir alafenamide (TAF). Studying seroconverters on early antiretroviral therapy (ART) minimizes the potential confounding impact of long-term HIV infection on cardiometabolic parameters. Methods Included individuals from CASCADE seroconverted 2007-2022, were ≥16 years, initiated ART…

Background People with HIV (PWH) have elevated risk for heart failure (HF). However, limited multi-center data exist on presentations and etiologies of HIV-associated HF. Methods We adjudicated incident HF events occurring between January 1, 2010 and December 31, 2023 at University of Washington (UW) and University of Alabama-Birmingham (UAB), which are two centers within the…

Background In people without HIV, high Coronary Artery Calcium Scores (CACS) correlate with an increased risk of major cardiovascular and cerebrovascular events (MACE). HIV is independently associated with raised CACS, however data on factors associated with increased CACS and MACE (except smoking and diabetes) in HIV are scarce. Although knowledge on the importance of statin…

Background Cardiovascular disease (CVD) risk in women living with HIV (WLWH) is shaped not only by traditional risk factors, but also by HIV-specific and women-specific factors. Primary prevention of CVD utilizes risk assessment models that show varying performance in WLWH. Predicting Risk of cardiovascular disease EVENTs (PREVENT) is a novel race/ethnicity-free sex-specific calculator that estimates…

Background CHIP (clonal hematopoiesis of indeterminate potential) mutations (hereafter ‘CHIP’) are acquired somatic DNA mutations that are associated with increased risk of cancer, mortality, and vascular disease. People with treated and suppressed HIV (PWH) have higher frequencies of CHIP than people without HIV (PWoH), but the underlying mechanisms linking CHIP and clinical events remains unclear…

Background Diastolic dysfunction (DD) is increasingly prevalent among people with HIV (PWH) and is associated with a heightened risk of subsequent heart failure (HF). Key mechanisms of HF include left ventricular hypertrophy (LVH), left atrial abnormalities and cardiac fibrosis. Additionally, soluble suppression of tumorigenicity 2 (sST2) has emerged as a potential biomarker for cardiac stress…

Background People with HIV (PWH) have an increased risk of cancer compared to the general population, even under antiretroviral therapy (ART); however, specific data in young PWH are lacking. Aim of the study was to assess the cancer risk of PWH aged <50 years in Italy. Methods Observational study in the Icona cohort enrolling ART-naïve PWH.…